ReviewCurrent urology reports2026
The Role of Micro-Ultrasound in Prostate Cancer Detection.
Review in Current urology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo synthesize current evidence on the role of 29-MHz micro-ultrasound (microUS) in prostate cancer (PCa) detection and to define its position relative to multiparametric MRI (mpMRI) across the diagnostic pathway. We conducted a narrative review of prospective, comparative, and randomized studies, with clinically significant prostate cancer (csPCa) detection as the primary endpoint. RECENT
findingsMicroUS provides ~ 70-µm axial resolution and enables real-time PRI-MUS-based risk stratification. Across head-to-head studies, microUS achieves diagnostic performance comparable to mpMRI. Evidence supports utility in biopsy-naïve patients, selected MRI-negative men with persistent clinical suspicion, repeat-biopsy settings, active surveillance, and local tumor staging, while combined mpMRI-microUS approaches have been shown to maximize yield of csPCa detection. Key limitations include operator dependence, interobserver variability, lack of validated biopsy-avoidance thresholds, and reduced sensitivity in anterior lesions. MicroUS is a practical, high-resolution platform that complements mpMRI and may enhance accessibility, efficiency, and precision in prostate cancer care.
Indexed as
Identifiers
42853344What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.